Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Santen Pharmaceutical Co stock

4536.T
JP3336000009
864318

Price

1,536.50
Today +/-
+0.06
Today %
+0.62 %

Santen Pharmaceutical Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Santen Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Santen Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Santen Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Santen Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Santen Pharmaceutical Co Stock Price History

DateSanten Pharmaceutical Co Price
2/4/20251,536.50 undefined
2/3/20251,527.00 undefined
1/31/20251,566.50 undefined
1/30/20251,555.00 undefined
1/29/20251,549.50 undefined
1/28/20251,566.00 undefined
1/27/20251,551.50 undefined
1/24/20251,555.50 undefined
1/23/20251,563.00 undefined
1/22/20251,555.00 undefined
1/21/20251,561.00 undefined
1/20/20251,561.00 undefined
1/17/20251,536.00 undefined
1/16/20251,533.50 undefined
1/15/20251,556.50 undefined
1/14/20251,565.50 undefined
1/10/20251,537.50 undefined
1/9/20251,580.00 undefined
1/8/20251,598.50 undefined
1/7/20251,610.00 undefined

Santen Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Santen Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Santen Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Santen Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Santen Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Santen Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Santen Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Santen Pharmaceutical Co’s growth potential.

Santen Pharmaceutical Co Revenue, EBIT and net profit per share

DateSanten Pharmaceutical Co RevenueSanten Pharmaceutical Co EBITSanten Pharmaceutical Co Net Income
2027e312.16 B undefined61.61 B undefined42.56 B undefined
2026e299.58 B undefined52.52 B undefined37.85 B undefined
2025e302.89 B undefined47.47 B undefined35.6 B undefined
2024301.97 B undefined52.69 B undefined26.63 B undefined
2023279.04 B undefined35.3 B undefined-14.96 B undefined
2022266.26 B undefined35.98 B undefined27.21 B undefined
2021249.61 B undefined37.56 B undefined9.31 B undefined
2020241.56 B undefined39.86 B undefined23.62 B undefined
2019234.03 B undefined41.39 B undefined31.95 B undefined
2018224.94 B undefined38.8 B undefined35.25 B undefined
2017199.1 B undefined32.48 B undefined21.73 B undefined
2016195.29 B undefined80.18 B undefined53.37 B undefined
2015161.83 B undefined35.37 B undefined24.03 B undefined
2014148.66 B undefined27.31 B undefined17.11 B undefined
2013119.07 B undefined24.68 B undefined16.52 B undefined
2012114.42 B undefined26.73 B undefined17.16 B undefined
2011110.81 B undefined30.74 B undefined21.33 B undefined
2010110.59 B undefined29.64 B undefined18.72 B undefined
2009101.62 B undefined15.49 B undefined10.12 B undefined
2008103.39 B undefined20.34 B undefined12.65 B undefined
2007100.49 B undefined20.06 B undefined13.15 B undefined
200698.4 B undefined20.67 B undefined13.02 B undefined
200592.7 B undefined18.66 B undefined11 B undefined

Santen Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
53.5461.365.4775.2277.9679.6483.5888.4588.9790.2589.8692.798.4100.49103.39101.62110.59110.81114.42119.07148.66161.83195.29199.1224.94234.03241.56249.61266.26279.04301.97302.89299.58312.16
-14.506.8014.883.642.164.945.830.591.45-0.443.166.152.122.89-1.728.830.203.254.0624.868.8620.681.9512.984.043.223.336.674.808.220.31-1.094.20
65.6467.1068.1163.7559.8958.9861.5062.2863.2564.2464.5563.6364.9064.6964.6964.6368.6168.9269.0765.1460.9265.1762.7162.3561.6061.2260.7460.6558.8159.5259.1859.0059.6557.25
35.1541.1444.5947.9546.6946.9751.455.0956.2757.985858.9963.866566.8865.6775.8876.3879.0377.5790.56105.46122.46124.13138.56143.26146.72151.38156.59166.09178.71000
6.888.0211.6897.328.117.947.715.318.476.31113.0213.1512.6510.1218.7221.3317.1616.5217.1124.0353.3721.7335.2531.9523.629.3127.21-14.9626.6335.637.8542.56
-16.4845.65-22.94-18.6210.69-2.02-2.87-31.2259.72-25.6574.5718.400.96-3.78-19.9884.9513.95-19.56-3.733.5740.46122.09-59.2862.20-9.34-26.09-60.59192.38-154.96-278.0933.646.3312.43
----------------------------------
----------------------------------
318350392450516515515514500498440437434434433425426428436422414414.86415.65411.88407.87407.4400.25400.39400.46387.42368.14000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Santen Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Santen Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                             
23.9727.8321.3625.0526.1935.0536.230.4828.3230.9142.9332.9945.7851.2151.3548.5165.6878.8978.9761.8976.6266.13100.0553.6369.7671.0691.8863.4284.3158.6894.96
10.7514.6217.0230.7929.229.5831.7740.8339.3532.3832.235.6134.4235.0335.6136.0135.2738.9837.9243.8452.0859.6163.9568.876.1281.9684.2293.0395.99103.6186.95
10.979.8912.390000000000000000002.092.052.172.542.662.782.963.63.623.59
4.496.117.937.669.299.1411.1811.9912.3711.6810.399.839.8410.3611.3312.2313.6214.717.9520.9520.0320.132528.530.6435.2435.2841.5837.1439.3543.19
0.220.21.15.566.224.253.074.736.038.465.74.313.854.224.464.294.265.095.445.917.272.713.693.914.323.834.395.258.398.077.45
50.3958.6459.7969.0670.8978.0282.2288.0286.0683.4391.2382.7393.89100.82102.75101.05118.83137.66140.29132.58156.01150.67194.74157.01183.37194.74218.56206.23229.43213.33236.14
19.224.842.9247.2843.4239.6437.4136.6842.1640.8537.2432.6830.430.4929.8528.6626.5824.9625.5227.4227.6329.127.9928.5529.7131.735.639.4956.2966.1771.58
5.376.316.369.7810.2719.1418.9221.9216.2115.7515.9620.222.8224.9719.6413.3313.5413.6513.6121.0525.434.7344.5429.8935.7830.0430.8537.0736.2437.3624.41
0.761.251.311.351.410000000000000000000000000.060
0.040.060.090.220.230.333.433.232.893.172.672.32.242.391.931.551.230.997.088.1910.2977.8677.24116.17112.2108.497.72103.1116.588.9275.52
0008.026.935.911.81.562.281.611.331.020.710.390.30005.85.946.306.4422.7722.322.7122.1312.713.727.398.3
1.531.722.24.515.671.876.181.832.52.331.811.050.390.052.076.416.77.546.54.465.495.274.454.525.123.593.916.697.818.0119.76
26.8934.1452.8871.1567.9366.8967.7565.2166.0463.715957.2456.5658.2853.7949.9648.0547.1358.5167.0675.1146.95160.66201.9205.1196.44190.21199.05230.55207.91199.56
77.2892.78112.67140.22138.82144.91149.96153.24152.1147.14150.23139.97150.45159.09156.54151.01166.87184.79198.8199.64231.11297.62355.4358.91388.46391.19408.77405.29459.98421.24435.7
                                                             
5.765.775.786.156.186.186.186.216.216.216.216.256.326.386.426.466.546.616.697.087.267.387.77.798.038.258.378.538.678.78.78
6.466.476.476.856.876.876.876.96.916.916.916.947.017.087.117.157.237.978.057.787.968.088.398.428.668.668.758.959.379.799.85
34.9242.2152.9462.8569.0175.9282.6683.7483.8990.5591.8495.9104.13111.7117.91121.32133.31147.88156.38151.33160.51179.39222.66224.11250.2259.46274.11273.76290.86238.4240.21
0000000-3.26-2.38-3.57-2.85-2.83-2.74-1.62-1.67-4.38-4.66-5.62-6.31-2.971.4516.942.615.334.585.431.538.8120.8729.5342.75
00000001.290.470.291.432.0545.212.27-0.250.14-0.440.051.924.04009.4714.3610.2311.1511.088.447.925.48
47.1454.4565.1975.8582.0788.9895.7294.8795.11100.4103.54108.31118.73128.75132.04130.3142.56156.4164.87165.13181.22211.8241.36255.12285.83292.03303.9311.12338.21294.34307.07
1.041.971.358.896.995.965.086.94.85.485.046.125.636.095.636.025.66.038.079.2714.2714.3317.2317.8822.4729.8222.7724.2624.4225.2824.04
1.922.22.152.053.192.442.592.672.312.432.232.482.482.482.612.592.692.712.943.093.570000000000
8.6112.269.3213.399.4713.113.6317.1417.811.3719.4713.3515.8313.6313.1413.1716.4515.3616.4114.6621.2530.246.4726.2735.6330.3439.1151.3857.4461.1766.01
6.065.6215.622.260.0500000000000.550.5400000000000000
0.320.321.270.574.712.650.650.631.4220.360.420.270.170.175.170.110000009.549.334.10.55.732.9113.973.062.75
17.9522.3729.7127.1724.4124.1521.9627.3426.3339.6327.1522.2224.1122.3726.5622.4425.2824.127.4327.0139.0944.5373.2353.4862.260.6667.678.5595.8289.592.8
7.719.3711.6931.1826.4625.7525.0924.4623.052.6912.276.615.455.280.110.040.070.150.120.090.0625.3512.947.623.53.566.67.2318.9733.1531.86
0000000.040.040.030.030.030.020.020.430.020.020.020.0222.272.82.873.9917.9612.919.397.233.632.531.591.38
4.486.586.086.115.956.057.26.567.587.677.292.882.242.382.743.143.94.124.45.147.957.865.2323.9122.32524.786.235.823.644.3
12.1915.9517.7737.2932.4131.832.3431.0730.6710.3819.589.527.718.082.873.23.994.296.517.510.836.0822.1649.538.7137.9538.6117.0927.3138.3837.53
30.1438.3247.4864.4656.8255.9654.2958.45750.0246.7331.7331.8230.4529.4225.6429.2728.3933.9434.5149.980.6195.39102.98100.9198.61106.2195.64123.13127.88130.33
77.2892.78112.68140.31138.89144.93150.01153.28152.1150.42150.27140.05150.54159.2161.46155.94171.83184.8198.8199.64231.11292.41336.75358.1386.74390.65410.11406.75461.34422.23437.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Santen Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Santen Pharmaceutical Co's financial health and stability.

Assets

Santen Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Santen Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Santen Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Santen Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
14.4215.5212.689.9513.7718.4420.3421.0420.4815.8228.6131.0727.7925.5926.8924.0353.3721.7235.2631.9421.716.6527.19-14.98
5.735.685.334.314.524.754.824.764.594.213.422.982.953.293.936.969.349.8810.910.9716.5716.7717.0617.25
000000000000000000000000
-13.41-14.34-11.371.216.44-14.66-4.74-10.51-9.82-8.93-7.04-16.16-8.95-18.61-5.27-17.2-66.13-30.35-7.42-16.38-12.71-30.62-6.45-12.7
2.64-0.030.310.34-1.54-1.910.46-0.330.220.751.11-0.13-0.31-0.330.4111.5925.959.594.116.3614.3746.018.2547.58
4614064644583281839591947146361632829852278190159240465
9.28.228.076-1.5311.246.518.917.768.438.2911.959.2710.377.0714.0913.0723.96.9913.4114.1512.8310.257.82
9.376.836.9515.8123.26.6220.8814.9615.4711.8526.1117.7721.489.9425.9625.3922.5310.8442.8432.8939.9538.8146.0437.15
-2,510-4,942-6,585-7,045-3,225-4,906-2,106-3,555-3,151-2,953-1,314-1,650-3,280-3,608-4,786-66,440-9,092-9,500-9,937-8,333-9,228-23,804-35,841-24,588
0.84-3.17-6.38-9.955.25-2.91-1.33-5.85-2.08-5.62-0.83-7.68-10.27-4.6-6.69-61.7137.05-28.2-8.26-2.94-5.18-53.36-35.17-26.78
3.351.770.21-2.918.4720.78-2.291.07-2.670.49-6.03-6.99-0.99-1.914.7346.14-18.71.685.44.05-29.550.67-2.19
000000000000000000000000
-2.65-0.65-0.62-1.42-10.36-5.8-1.27-0.17-0.17-4.62-0.08-0.5200037.03-14.63-6.52-8.32-3.53-1.88-5.6517.40.95
0-5.08-3.22-3.27-0-2.58-0.02-0.02-4.82-0.02-0.025.62-0-13.76-0.0100-12.38-0-14.12-0.0200-26.01
-3.82-7.19-5.68-6.51-12.12-12.71-5.9-5.69-11.42-11.37-6.75-1.57-8.56-21.56-7.9528.96-24.07-28.66-17.63-28.11-12.73-16.695.56-37.22
-0.030.060.02000.070.140.130.070.060.160.140.150.680.30.190.4911.250.13-0.450.150.150.45
-1,140-1,520-1,854-1,812-1,758-4,393-4,759-5,632-6,505-6,798-6,803-6,808-8,705-8,468-8,247-8,264-9,923-10,751-10,559-10,580-10,379-11,188-11,994-12,607
6.16-3.18-4.94-0.5716.37-9.0413.723.741.83-5.7218.398.142.55-15.2412.6-6.4733.88-47.52171.5120.63-28.5420.13-25.11
6,8631,8873618,76219,9701,71218,77011,40412,3178,89424,79516,11918,2036,33421,171-41,05413,4331,34332,90624,56130,71915,00410,20212,559
000000000000000000000000

Santen Pharmaceutical Co stock margins

The Santen Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Santen Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Santen Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Santen Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Santen Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Santen Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Santen Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Santen Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Santen Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Santen Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Santen Pharmaceutical Co Margin History

Santen Pharmaceutical Co Gross marginSanten Pharmaceutical Co Profit marginSanten Pharmaceutical Co EBIT marginSanten Pharmaceutical Co Profit margin
2027e59.18 %19.74 %13.63 %
2026e59.18 %17.53 %12.63 %
2025e59.18 %15.67 %11.75 %
202459.18 %17.45 %8.82 %
202359.52 %12.65 %-5.36 %
202258.81 %13.51 %10.22 %
202160.65 %15.05 %3.73 %
202060.74 %16.5 %9.78 %
201961.22 %17.69 %13.65 %
201861.6 %17.25 %15.67 %
201762.35 %16.31 %10.91 %
201662.71 %41.06 %27.33 %
201565.17 %21.86 %14.85 %
201460.92 %18.37 %11.51 %
201365.14 %20.73 %13.87 %
201269.07 %23.36 %15 %
201168.92 %27.74 %19.25 %
201068.61 %26.8 %16.93 %
200964.63 %15.25 %9.96 %
200864.69 %19.67 %12.23 %
200764.69 %19.96 %13.08 %
200664.9 %21 %13.23 %
200563.63 %20.13 %11.86 %

Santen Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Santen Pharmaceutical Co earnings per share therefore indicates how much revenue Santen Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Santen Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Santen Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Santen Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Santen Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Santen Pharmaceutical Co Revenue, EBIT and net profit per share

DateSanten Pharmaceutical Co Sales per ShareSanten Pharmaceutical Co EBIT per shareSanten Pharmaceutical Co Earnings per Share
2027e899.48 undefined0 undefined122.62 undefined
2026e863.23 undefined0 undefined109.06 undefined
2025e872.77 undefined0 undefined102.57 undefined
2024820.25 undefined143.13 undefined72.35 undefined
2023720.24 undefined91.12 undefined-38.6 undefined
2022664.88 undefined89.84 undefined67.95 undefined
2021623.41 undefined93.8 undefined23.25 undefined
2020603.51 undefined99.59 undefined59.01 undefined
2019574.44 undefined101.6 undefined78.43 undefined
2018551.5 undefined95.13 undefined86.42 undefined
2017483.38 undefined78.86 undefined52.76 undefined
2016469.84 undefined192.9 undefined128.41 undefined
2015390.09 undefined85.27 undefined57.93 undefined
2014359.09 undefined65.98 undefined41.33 undefined
2013282.15 undefined58.49 undefined39.15 undefined
2012262.42 undefined61.31 undefined39.36 undefined
2011258.91 undefined71.82 undefined49.84 undefined
2010259.61 undefined69.58 undefined43.95 undefined
2009239.1 undefined36.46 undefined23.82 undefined
2008238.79 undefined46.97 undefined29.21 undefined
2007231.53 undefined46.21 undefined30.29 undefined
2006226.72 undefined47.62 undefined30 undefined
2005212.12 undefined42.7 undefined25.17 undefined

Santen Pharmaceutical Co business model

Santen Pharmaceutical Co., Ltd. is a Japanese company specializing in the development and marketing of pharmaceutical products and medical devices. With its headquarters in Osaka, Japan, Santen was founded in October 1890 as Fukuhara Helper's Institute Co., Ltd. Santen started as a small contact lens manufacturer and distributor in 1936, focusing on producing and selling high-quality contact lenses. Over time, the company expanded its product offerings to include ophthalmic products such as eye drops and other medications. In the 1990s, Santen further expanded its business by acquiring other companies and establishing its own research and development department to develop innovative products. Today, Santen is part of a global network of companies specializing in the development and marketing of ophthalmic products. Santen operates in various business areas, including ophthalmology, dermatological and anti-rheumatic medications, as well as medical devices and diagnostic instruments. The company has a presence in over 60 countries worldwide, with branches in the USA, Europe, and Asia. In the field of ophthalmology, Santen offers a wide range of products for the treatment of eye diseases such as glaucoma, dry eye, and allergic conditions. The company has also developed advanced devices for ophthalmology, such as lasers for the treatment of various eye diseases. Santen has also invested in dermatological medicine by offering medications for various skin conditions, including acne, psoriasis, and eczema. Additionally, the company provides medical devices for the diagnosis and monitoring of skin conditions. Specializing in the development of anti-rheumatic medications, Santen offers therapies for conditions such as rheumatoid arthritis and psoriatic arthritis. The company has collaborated with other companies to develop innovations in this field. Santen's business model revolves around developing and marketing innovative products for the healthcare industry. The company aims to provide patients worldwide with access to the best treatments and medical devices. Santen prioritizes research and development, investing a significant portion of its revenue in the development of new products. Overall, Santen offers a wide range of products and services that are in high demand in the healthcare sector. The company has established itself as an innovative provider of top-quality solutions in ophthalmology, dermatology, and rheumatology worldwide. With its strong presence in various countries, Santen continues to invest in the research and introduction of new products that can improve the health and well-being of people. Santen Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Santen Pharmaceutical Co SWOT Analysis

Strengths

Santen Pharmaceutical Co Ltd boasts several strengths that contribute to its success and positioning in the market. Firstly, the company has a strong portfolio of innovative and high-quality pharmaceutical products across multiple therapeutic areas. This diverse range of offerings allows Santen to cater to a wide customer base and meet various medical needs.

Additionally, Santen has established itself as a leader in the ophthalmic industry. The company has a deep understanding of ocular health and has developed specialized expertise in this field. With this focus, Santen can provide targeted solutions for eye-related conditions, enabling it to gain a competitive edge.

Santen's commitment to research and development further strengthens its position. The company invests significant resources into innovation, continuously working to improve existing products and develop new treatments. This dedication to research enhances Santen's ability to stay ahead in the ever-evolving pharmaceutical industry.

Weaknesses

Despite its strengths, Santen Pharmaceutical Co Ltd faces certain weaknesses that can hinder its growth and performance. One notable weakness is its limited geographical presence. The company primarily operates within the Asian market, which limits its access to other potentially lucrative regions. Expanding into new markets could provide Santen with opportunities for further growth and revenue generation.

Furthermore, Santen's heavy reliance on a specific therapeutic area, namely ophthalmology, exposes it to potential risks. Any adverse developments in this field could significantly impact the company's financial performance. Diversifying its product offerings across various therapeutic areas could mitigate this vulnerability.

Opportunities

Santen Pharmaceutical Co Ltd operates in an industry with numerous opportunities for expansion and development. The growing global population, particularly in aging societies, presents a significant opportunity for the company. Age-related eye diseases, such as cataracts and glaucoma, are becoming more prevalent, creating a higher demand for ophthalmic treatments and medications. Santen can capitalize on this trend by developing innovative solutions tailored to address the specific needs of these patients.

Additionally, expanding into new markets, especially in regions with emerging economies, offers considerable growth potential. By establishing a presence in these markets, Santen can tap into a larger customer base and leverage increasing healthcare expenditure in these regions.

Threats

Santen Pharmaceutical Co Ltd faces certain threats that could impact its operations and market position. One significant threat is the intense competition within the pharmaceutical industry. Numerous companies are vying for market share, and Santen must continuously innovate and differentiate itself to retain its competitive advantage.

Furthermore, regulatory challenges and the need for stringent compliance pose potential threats. Adhering to various regulations and maintaining high safety standards across different markets can be complex and costly. Failure to comply could result in legal consequences and damage to the company's reputation.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Santen Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Santen Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Santen Pharmaceutical Co shares outstanding

The number of shares was Santen Pharmaceutical Co in 2024 — This indicates how many shares 368.139 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Santen Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Santen Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Santen Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Santen Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Santen Pharmaceutical Co stock splits

In Santen Pharmaceutical Co's history, there have been no stock splits.

Santen Pharmaceutical Co dividend history and estimates

In 2024, Santen Pharmaceutical Co paid a dividend amounting to 34 JPY. Dividend means that Santen Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Santen Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Santen Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Santen Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Santen Pharmaceutical Co Dividend History

DateSanten Pharmaceutical Co Dividend
2027e34.66 undefined
2026e34.67 undefined
2025e34.87 undefined
202434 undefined
202332 undefined
202232 undefined
202130 undefined
202028 undefined
201926 undefined
201826 undefined
201726 undefined
201626 undefined
201524 undefined
201420 undefined
201320 undefined
201220 undefined
201120 undefined
201016 undefined
200916 undefined
200816 undefined
200715 undefined
200613 undefined
200511 undefined

Santen Pharmaceutical Co dividend payout ratio

In 2024, Santen Pharmaceutical Co had a payout ratio of 83.53%. The payout ratio indicates the percentage of the company's profits that Santen Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Santen Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Santen Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Santen Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Santen Pharmaceutical Co Payout Ratio History

DateSanten Pharmaceutical Co Payout ratio
2027e75.79 %
2026e75.47 %
2025e68.37 %
202483.53 %
202374.51 %
202247.08 %
2021129 %
202047.45 %
201933.15 %
201830.09 %
201749.28 %
201620.25 %
201541.43 %
201448.39 %
201351.1 %
201250.83 %
201140.13 %
201036.41 %
200967.2 %
200854.78 %
200749.52 %
200643.33 %
200543.72 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Santen Pharmaceutical Co.

Santen Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/202421.91 23.29  (6.3 %)2025 Q2
6/30/202422.39 29.59  (32.13 %)2025 Q1
3/31/202413.78 0.33  (-97.61 %)2024 Q4
12/31/202315.36 20.2  (31.49 %)2024 Q3
9/30/202313.32 24.13  (81.16 %)2024 Q2
6/30/202317.37 27.93  (60.84 %)2024 Q1
12/31/202214.14 14.92  (5.52 %)2023 Q3
9/30/20229.76 -72.84  (-846.57 %)2023 Q2
6/30/202216.69 19.55  (17.17 %)2023 Q1
3/31/202219.81 19.68  (-0.64 %)2022 Q4
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Santen Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

89/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

68

Environment

Scope 1 - Direct Emissions
16,948
Scope 2 - Indirect emissions from purchased energy
21,390
Scope 3 - Indirect emissions within the value chain
133,451
Total CO₂ emissions
38,338
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees42.8
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Santen Pharmaceutical Co shareholders

%
Name
Stocks
Change
Date
5.51544 % Nomura Asset Management Co., Ltd.19,140,800-3,771,6005/31/2024
5.27043 % Silchester International Investors, L.L.P.18,290,50018,290,5004/19/2024
3.96145 % MFS Investment Management13,747,800-4,798,30010/31/2023
3.95875 % Black Creek Investment Management, Inc.13,738,4444,486,53010/15/2024
3.26729 % Sumitomo Mitsui Trust Asset Management Co., Ltd.11,338,800-2,886,7008/31/2023
3.07227 % Nippon Life Insurance Company10,662,00003/31/2024
2.83319 % Mitsubishi UFJ Trust and Banking Corporation9,832,300-301,8007/22/2024
2.44917 % The Vanguard Group, Inc.8,499,598-183,7009/30/2024
2.36362 % Nikko Asset Management Co., Ltd.8,202,700-2,814,1008/31/2023
2.06172 % Norges Bank Investment Management (NBIM)7,155,000-452,0003/31/2024
1
2
3
4
5
...
10

Santen Pharmaceutical Co Executives and Management Board

Mr. Akira Kurokawa

(70)
Santen Pharmaceutical Co Chairman of the Board, Representative Director (since 2006)
Compensation 138 M

Mr. Takeshi Ito

(64)
Santen Pharmaceutical Co President, Chief Executive Officer, Representative Director (since 2017)
Compensation 116 M

Mr. Kazuo Koshiji

Santen Pharmaceutical Co Chief Financial Officer, Chief Risk Officer, Executive Officer

Mr. Rie Nakajima

Santen Pharmaceutical Co Chief Operating Officer, Executive Officer

Mr. Minori Hara

Santen Pharmaceutical Co Executive Officer, Chief Digital & Information Officer (since 2022)
1
2
3
4
5
...
6

Santen Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Medipal Holdings Stock
Medipal Holdings
SupplierCustomer0,880,090,620,140,46-0,23
Daiichi Sankyo Stock
Daiichi Sankyo
SupplierCustomer0,85-0,36-0,760,08-0,090,37
Ono Pharmaceutical Stock
Ono Pharmaceutical
SupplierCustomer0,85-0,58-0,72-0,88-0,810,42
PALTAC Stock
PALTAC
SupplierCustomer0,78-0,490,260,450,500,46
Nicox Stock
Nicox
SupplierCustomer0,650,450,850,930,790,60
Suzuken Stock
Suzuken
SupplierCustomer0,64-0,59-0,55-0,84-0,800,35
CSL Stock
CSL
SupplierCustomer0,53-0,19-0,380,730,800,43
UBE Stock
UBE
SupplierCustomer0,39-0,550,540,180,59-0,47
Merck & Co Stock
Merck & Co
SupplierCustomer0,390,08-0,76-0,51-0,40-0,27
Mitsubishi Chemical Hldgs Stock
Mitsubishi Chemical Hldgs
SupplierCustomer0,340,260,550,800,88-0,60
1
2

Most common questions regarding Santen Pharmaceutical Co

What values and corporate philosophy does Santen Pharmaceutical Co represent?

Santen Pharmaceutical Co Ltd is a renowned company known for its core values and corporate philosophy. Committed to improving ophthalmic healthcare, Santen focuses on integrity, innovation, and dedication to patients worldwide. The company prioritizes delivering effective and safe solutions, aiming to contribute to the well-being of patients and the global community. Santen Pharmaceutical Co Ltd values ethical business conduct, transparency, and sustainable practices. With a strong emphasis on research and development, Santen continuously strives to enhance existing treatments and develop advanced therapeutic options. Passionate about providing innovative solutions, Santen Pharmaceutical Co Ltd is dedicated to improving vision and quality of life for individuals affected by ocular diseases.

In which countries and regions is Santen Pharmaceutical Co primarily present?

Santen Pharmaceutical Co Ltd is primarily present in various countries and regions across the globe. The company has a significant presence in Japan, where it is headquartered. In addition to its home market, Santen Pharmaceutical Co Ltd has established a strong foothold in various regions including North America, Europe, Asia-Pacific, and Latin America. The company's commitment to expansion and growth has allowed it to serve a diverse customer base across multiple countries and regions, further strengthening its global presence and market position.

What significant milestones has the company Santen Pharmaceutical Co achieved?

Santen Pharmaceutical Co Ltd has achieved several significant milestones throughout its history. Founded in 1890, the company has become a global leader in ophthalmic pharmaceuticals and medical devices. Santen Pharmaceutical Co Ltd has made groundbreaking advancements in the treatment of various eye conditions, such as glaucoma, dry eye syndrome, and retinal diseases. With a strong focus on research and development, the company has introduced innovative products and technologies that improve vision and enhance patients' quality of life. Santen Pharmaceutical Co Ltd continues to expand its global presence and collaborate with leading healthcare professionals to address unmet medical needs in the field of ophthalmology.

What is the history and background of the company Santen Pharmaceutical Co?

Santen Pharmaceutical Co Ltd is a renowned Japanese company specializing in the research, development, and commercialization of ophthalmic medical products and treatments. Established in 1890, Santen Pharmaceutical has a rich history spanning over a century. The company's dedication to innovation and advanced technologies has led to numerous breakthroughs in eye care. Santen Pharmaceutical pioneers novel therapies for ocular diseases, including glaucoma, dry eye syndrome, and age-related macular degeneration. By consistently prioritizing patient needs and leveraging its scientific expertise, Santen Pharmaceutical continues to be a global leader in ophthalmic pharmaceuticals, bringing sight-saving solutions to millions worldwide.

Who are the main competitors of Santen Pharmaceutical Co in the market?

The main competitors of Santen Pharmaceutical Co Ltd in the market include multinational pharmaceutical companies such as Novartis, Allergan, and Pfizer. These companies also specialize in developing and marketing ophthalmic pharmaceutical products, which directly compete with Santen Pharmaceutical's portfolio. Additionally, local companies like Sun Pharmaceutical Industries in India and Daiichi Sankyo in Japan may pose competition in specific regions. Santen Pharmaceutical Co Ltd continually strives to maintain a competitive edge by focusing on innovative research and development, strategic partnerships, and expanding its global presence.

In which industries is Santen Pharmaceutical Co primarily active?

Santen Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Santen Pharmaceutical Co?

The business model of Santen Pharmaceutical Co Ltd revolves around developing and marketing innovative pharmaceutical products and medical devices for the field of ophthalmology. Santen focuses on providing solutions that address various eye diseases and conditions, including glaucoma, dry eye syndrome, and cataracts. By conducting extensive research and clinical trials, Santen aims to improve the quality of life for individuals suffering from ophthalmic disorders. Through strategic partnerships, targeted marketing, and continuous investment in research and development, Santen Pharmaceutical Co Ltd aims to position itself as a leading provider of ophthalmic treatments worldwide.

What is the P/E ratio of Santen Pharmaceutical Co 2025?

The Santen Pharmaceutical Co P/E ratio is 15.89.

What is the P/S ratio of Santen Pharmaceutical Co 2025?

The Santen Pharmaceutical Co P/S ratio is 1.87.

What is the Quality Investing of Santen Pharmaceutical Co?

The Quality Investing for Santen Pharmaceutical Co is 6/10.

What is the revenue of Santen Pharmaceutical Co 2025?

The expected Santen Pharmaceutical Co revenue is 302.89 B JPY.

How high is the profit of Santen Pharmaceutical Co 2025?

The expected Santen Pharmaceutical Co profit is 35.6 B JPY.

What is the business model of Santen Pharmaceutical Co

Santen Pharmaceutical Co Ltd is one of the leading Japanese companies in the production and marketing of pharmaceutical products. Its business activities include various segments, including research, development, manufacturing, and marketing of medications, medical devices, and cosmetic products. The company specializes in the development and manufacturing of eye preparations, particularly medications for the treatment of diseases such as glaucoma, dry eye, allergic conjunctivitis, infectious conjunctivitis, and other eye conditions. Santen also operates in the medical devices sector, offering advanced technology such as optical coherence tomography devices for the diagnosis and management of eye diseases. In recent years, the company has expanded its business field to the cosmetics market with its beauty brand Hada Labo, offering a range of skincare products specifically designed for sensitive skin. Santen also collaborates with other pharmaceutical companies to develop new technologies and therapeutics for eye diseases and other medical indications. The company is committed to innovation and research, with research and development sites in Europe, the USA, and Asia. Santen invests significant amounts in research and development to stay innovative and bring new products to market, shaping the future of ophthalmology. In summary, Santen Pharmaceutical Co Ltd offers a wide range of products and services tailored to the needs of patients, eye doctors, cosmetic enthusiasts, and pharmaceutical partners. The company is a key player in global ophthalmology and continuously invests in innovation and research to meet the needs of its customers and partners.

What is the Santen Pharmaceutical Co dividend?

Santen Pharmaceutical Co pays a dividend of 32 JPY distributed over 2 payouts per year.

How often does Santen Pharmaceutical Co pay dividends?

Santen Pharmaceutical Co pays out a dividend 2 times a year.

What is the Santen Pharmaceutical Co ISIN?

The ISIN of Santen Pharmaceutical Co is JP3336000009.

What is the Santen Pharmaceutical Co WKN?

The WKN of Santen Pharmaceutical Co is 864318.

What is the Santen Pharmaceutical Co ticker?

The ticker of Santen Pharmaceutical Co is 4536.T.

How much dividend does Santen Pharmaceutical Co pay?

Over the past 12 months, Santen Pharmaceutical Co paid a dividend of 34 JPY . This corresponds to a dividend yield of about 2.21 %. For the coming 12 months, Santen Pharmaceutical Co is expected to pay a dividend of 34.67 JPY.

What is the dividend yield of Santen Pharmaceutical Co?

The current dividend yield of Santen Pharmaceutical Co is 2.21 %.

When does Santen Pharmaceutical Co pay dividends?

Santen Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Santen Pharmaceutical Co?

Santen Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Santen Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 34.67 JPY are expected. This corresponds to a dividend yield of 2.26 %.

In which sector is Santen Pharmaceutical Co located?

Santen Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Santen Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Santen Pharmaceutical Co from 6/1/2025 amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2025.

When did Santen Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 6/1/2025.

What was the dividend of Santen Pharmaceutical Co in the year 2024?

In the year 2024, Santen Pharmaceutical Co distributed 32 JPY as dividends.

In which currency does Santen Pharmaceutical Co pay out the dividend?

The dividends of Santen Pharmaceutical Co are distributed in JPY.

All fundamentals about Santen Pharmaceutical Co

Our stock analysis for Santen Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Santen Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.